Skip to main content
Fig. 2 | Pediatric Rheumatology

Fig. 2

From: The PRINTO evidence-based proposal for glucocorticoids tapering/discontinuation in new onset juvenile dermatomyositis patients

Fig. 2

Trend of the PRINTO CSM and MMT in the 3 groups of children with JDM. [A = MD-global: physician’s global assessment of the patient’s overall disease activity on a 0–10-cm visual analogue scale (VAS); B=Parent global: parents’ global assessment of the child’s overall patient’s well-being on a 10-cm VAS; C = DAS: Disease Activity Score (range 0–20); D = CHAQ: cross-culturally adapted and validated version of the Childhood Health Assessment Questionnaire (range 0–3); E = CMAS: Childhood Myositis Assessment Scale (range 0–52); F = MMT: manual muscle testing (range 0–80); G = PhS: physical summary score of the Child Health Questionnaire (range 40–60)]

Back to article page